Infection Due to Resistant Bacteria
6
0
0
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
17%
1 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (6)
Resistant Bacteria in Children in France
Study of Accuracy of New Diagnostic Technology to Determine Guide Rapid Antibiotic Treatment for Serious Infections
Study of Accuracy of New Diagnostic Technology to Guide Rapid Antibiotic Treatment for Serious Infections
Colistin Pharmacokinetics in Critically Ill Patients During Extended Dialysis
International Travel and the Spread of Extended-spectrum Beta-lactamase-producing Escherichia Coli
Colistin and Rifampicin for MDR-Acinetobacter